Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) have earned a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $65.58.
GBT has been the subject of several research reports. Cantor Fitzgerald set a $61.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, December 11th. HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, December 11th. Nomura increased their price target on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a research report on Monday, December 11th. BidaskClub upgraded shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Finally, Oppenheimer set a $79.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 12th.
In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now owns 140,055 shares in the company, valued at $4,201,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Radovich sold 12,500 shares of the stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the transaction, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold 88,500 shares of company stock valued at $3,003,350 in the last quarter. Company insiders own 5.30% of the company’s stock.
Shares of Global Blood Therapeutics (NASDAQ:GBT) traded up $0.55 during mid-day trading on Monday, hitting $36.80. 1,162,668 shares of the stock traded hands, compared to its average volume of 1,041,849. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.
Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the firm posted ($0.58) EPS. sell-side analysts expect that Global Blood Therapeutics will post -2.55 EPS for the current year.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.